Tear film evaporation

"Tear film evaporation" refers to the **physical process by which water is lost from the ocular surface via vaporization through the tear film**. It is not a molecule, protein, receptor, enzyme, or other discrete biological target. Instead, it is a physiological phenomenon central to maintaining ocular surface health. The **tear film** consists of three layers—lipid (outermost), aqueous-mucin (middle), and mucin/glycocalyx (innermost)—with the **lipid layer**, secreted primarily by the meibomian glands, serving as a critical barrier that retards water loss[1][4][2]. Disruption in this barrier—often due to lipid deficiency or meibomian gland dysfunction—leads to increased tear evaporation and contributes significantly (~90%) to dry eye disease cases[1][4]. Excessive tear evaporation results in hyperosmolarity of tears and subsequent inflammation and damage of the ocular surface[1][3]. Because "tear film evaporation" describes a process rather than an actionable molecular entity or druggable target, it should not be classified as a canonical therapeutic target. The nonpolar phase (mainly composed of wax esters and cholesterol esters) provides the air–tear interface and is responsible for retarding evaporation... A normal tear film lipid layer can reduce evaporation by approximately 90%–95%.[4] Reduction of [water] evaporation is likely due to organized crystalline layers within the TFLL at the water–lipid interface.[2] In summary: **Tear film evaporation** is *not* an individual molecule/receptor/target but rather an important physiological process relevant in ophthalmology. Therapeutic strategies focus on restoring normal function/composition of components that regulate this process—primarily targeting meibomian gland health/lipid secretion—not directly inhibiting "evaporation" itself[1][2][4].

Other names

Tear evaporationEvaporative tear lossTear film water loss